Literature DB >> 18452826

Statistical issues in the evaluation of screening and early detection modalities.

Ruth Etzioni1.   

Abstract

Thorough evaluation of a screening test requires conducting a series of studies to ascertain its ability to detect accurately disease, as well as its benefits and costs. In this article, I review the steps involved in evaluating a screening test, using the case of prostate-specific antigen (PSA) screening for prostate cancer as a case study. I discuss designs for quantifying the diagnostic properties of a screening test and compare several different studies that have produced quite different estimates of the diagnostic accuracy of PSA screening. I also review methods that may be used to combine other markers or tests with PSA to improve test accuracy. Determining the benefits of a screening test is complex, particularly when information from randomized trials is lacking. I review several observational studies of PSA benefit and discuss the use of computer models for inferring the impact of screening from trends in population mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18452826     DOI: 10.1016/j.urolonc.2006.11.008

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

1.  New Prognostic Markers: The Pathway from Research to Clinical Practice.

Authors:  Caroline Savage; Andrew J Vickers
Journal:  Grand rounds Urol       Date:  2009-08

2.  α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues.

Authors:  Bin Ouyang; Yuet-Kin Leung; Vinson Wang; Ethan Chung; Linda Levin; Bruce Bracken; Liang Cheng; Shuk-Mei Ho
Journal:  Urology       Date:  2011-01       Impact factor: 2.649

3.  The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer.

Authors:  May Al-Maghrebi; Elijah O Kehinde; Jehoram T Anim; Mehraj Sheikh
Journal:  Int Urol Nephrol       Date:  2012-06-21       Impact factor: 2.370

4.  A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.

Authors:  Bin Ouyang; Bruce Bracken; Barbara Burke; Ethan Chung; Juan Liang; Shuk-Mei Ho
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

5.  Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Authors:  Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.